On Friday, Day One Biopharmaceuticals Inc (NASDAQ: DAWN) opened higher 1.46% from the last session, before settling in for the closing price of $6.16. Price fluctuations for DAWN have ranged from $6.08 to $16.76 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Company’s average yearly earnings per share was noted -35.23% at the time writing. With a float of $74.24 million, this company’s outstanding shares have now reached $101.35 million.
The firm has a total of 181 workers. Let’s measure their productivity. In terms of profitability, gross margin is 94.96%, operating margin of -118.31%, and the pretax margin is -38.25%.
Day One Biopharmaceuticals Inc (DAWN) Insider Activity
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Day One Biopharmaceuticals Inc is 26.76%, while institutional ownership is 84.31%. The most recent insider transaction that took place on May 16 ’25, was worth 26,796. Before that another transaction happened on May 16 ’25, when Company’s Officer proposed sale 3,927 for $6.26, making the entire transaction worth $24,575.
Day One Biopharmaceuticals Inc (DAWN) Earnings and Forecasts
According to the Wall Street analysts, stocks earnings will be around -35.23% per share during the next fiscal year.
Day One Biopharmaceuticals Inc (NASDAQ: DAWN) Trading Performance Indicators
Check out the current performance indicators for Day One Biopharmaceuticals Inc (DAWN). In the past quarter, the stock posted a quick ratio of 10.55. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 3.91.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.67, a number that is poised to hit -0.35 in the next quarter and is forecasted to reach -0.84 in one year’s time.
Technical Analysis of Day One Biopharmaceuticals Inc (DAWN)
Analysing the last 5-days average volume posted by the [Day One Biopharmaceuticals Inc, DAWN], we can find that recorded value of 1.76 million was better than the volume posted last year of 1.25 million. As of the previous 9 days, the stock’s Stochastic %D was 6.94%. Additionally, its Average True Range was 0.49.
During the past 100 days, Day One Biopharmaceuticals Inc’s (DAWN) raw stochastic average was set at 2.28%, which indicates a significant decrease from 8.46% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 69.80% in the past 14 days, which was higher than the 67.56% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $7.54, while its 200-day Moving Average is $11.85. Now, the first resistance to watch is $6.35. This is followed by the second major resistance level at $6.46. The third major resistance level sits at $6.59. If the price goes on to break the first support level at $6.11, it is likely to go to the next support level at $5.98. Should the price break the second support level, the third support level stands at $5.87.
Day One Biopharmaceuticals Inc (NASDAQ: DAWN) Key Stats
There are currently 101,362K shares outstanding in the company with a market cap of 633.52 million. Presently, the company’s annual sales total 131,160 K according to its annual income of -95,500 K. Last quarter, the company’s sales amounted to 30,760 K and its income totaled -36,000 K.
